Search

Your search keyword '"Santos, Ernestina"' showing total 342 results
Start Over Author "Santos, Ernestina"
342 results on '"Santos, Ernestina"'

2. Stroke frequency, associated factors, and clinical features in primary systemic vasculitis: a multicentric observational study

Author

Geraldes, Ruth, Santos, Monica, Ponte, Cristina, Craven, Anthea, Barra, Lillian, Robson, Joanna C., Hammam, Nevin, Springer, Jason, Henes, Jöerg, Hocevar, Alojzija, Putaala, Jukka, Santos, Ernestina, Rajasekhar, Liza, Daikeler, Thomas, Karadag, Omer, Costa, Andreia, Khalidi, Nader, Pagnoux, Christian, Canhão, Patrícia, Melo, Teresa Pinho e, Fonseca, Ana Catarina, Ferro, José M., Fonseca, João Eurico, Suppiah, Ravi, Watts, Richard A., Grayson, Peter, Merkel, Peter A., and Luqmani, Raashid A.

Published
2024
Full Text
View/download PDF

4. Blood neutrophils, oligoclonal bands and bridging corticosteroids as predictive factors for MOGAD course: Insights from a multicentric Portuguese cohort

Author

Neves, Ana Lídia, Cabral, Andrea, Serrão, Catarina, Oliveira, Daniela Santos, Alves, Janice, Alves, José Miguel, Soares, Mafalda, Santos, Ernestina, Seabra, Mafalda, Felgueiras, Helena, Ferreira, João, Brandão, Eva, Guerreiro, Rui, Nunes, Carla Cecília, Ladeira, Filipa, Vale, José, Sá, Maria José, and Jorge, André

Published
2024
Full Text
View/download PDF

6. Prognostic factors associated with disability in a cohort of neuromyelitis optica spectrum disorder and MOG-associated disease from a nationwide Portuguese registry

Author

Moura, João, Samões, Raquel, Sousa, Ana Paula, Figueiroa, Sónia, Mendonça, Teresa, Abreu, Pedro, Guimarães, Joana, Melo, Claúdia, Sousa, Raquel, Soares, Mafalda, Correia, Ana Sofia, Marques, Inês Brás, Perdigão, Sandra, Alves, Ivânia, Felgueiras, Helena, Nzwalo, Hipólito, Mendes, Irene, Almeida, Vânia, Boleixa, Daniela, Carneiro, Paula, Neves, Esmeralda, Silva, Ana Martins, Sá, Maria José, and Santos, Ernestina

Published
2024
Full Text
View/download PDF

10. Late onset neuromyelitis optica spectrum disorders (LONMOSD) from a nationwide Portuguese study: Anti-AQP4 positive, anti-MOG positive and seronegative subgroups

Author

Santos, Ernestina, Moura, João, Samões, Raquel, Sousa, Ana Paula, Mendonça, Teresa, Abreu, Pedro, Guimarães, Joana, Correia, Inês, Durães, Joao, Sousa, Lívia, Ferreira, João, de Sá, João, Sousa, Filipa, Sequeira, Marta, Correia, Ana Sofia, André, Ana Luísa, Basílio, Carlos, Arenga, Marta, Marques, Inês Brás, Perdigão, Sandra, Alves, Ivânia, Santos, Mariana, Salgado, Vasco, Palos, Adelaide, Guerreiro, Rui, Isidoro, Luís, Boleixa, Daniela, Carneiro, Paula, Neves, Esmeralda, Silva, Ana Martins, Gonçalves, Guilherme, and Sá, Maria José

Published
2022
Full Text
View/download PDF

13. Neuromyelitis optica spectrum disorders: A nationwide Portuguese clinical epidemiological study

Author

Santos, Ernestina, Rocha, Ana Luísa, Oliveira, Vanessa, Ferro, Daniela, Samões, Raquel, Sousa, Ana Paula, Figueiroa, Sónia, Mendonça, Teresa, Abreu, Pedro, Guimarães, Joana, Sousa, Raquel, Melo, Cláudia, Correia, Inês, Durães, Joao, Sousa, Lívia, Ferreira, João, de Sá, João, Sousa, Filipa, Sequeira, Marta, Correia, Ana Sofia, André, Ana Luísa, Basílio, Carlos, Arenga, Marta, Mendes, Irene, Marques, Inês Brás, Perdigão, Sandra, Felgueiras, Helena, Alves, Ivânia, Correia, Filipe, Barroso, Cândida, Morganho, Armando, Carmona, Cátia, Palavra, Filipe, Santos, Mariana, Salgado, Vasco, Palos, Adelaide, Nzwalo, Hipólito, Timóteo, Angela, Guerreiro, Rui, Isidoro, Luís, Boleixa, Daniela, Carneiro, Paula, Neves, Esmeralda, Silva, Ana Martins, Gonçalves, Guilherme, Leite, Maria Isabel, and Sá, Maria José

Published
2021
Full Text
View/download PDF

19. Neurological Involvement in a Portuguese Cohort of IgG4-Related Disease

Author

Moura, João, primary, Malaquias, Maria João, additional, Jorge, Firmina, additional, Pinto, Eduarda, additional, Sardoeira, Ana, additional, Laranjinha, Inês, additional, Oliveira, Vanessa, additional, Sousa, Ana Paula, additional, Damásio, Joana, additional, Maia, Luís, additional, Vila-Chã, Nuno, additional, Samões, Raquel, additional, Taipa, Ricardo, additional, Martins da Silva, Ana, additional, and Santos, Ernestina, additional

Published
2024
Full Text
View/download PDF

28. MuSK myasthenia gravis and pregnancy

Author

Santos, Ernestina, Braga, Antonio, Gabriel, Denis, Duarte, Sara, Martins da Silva, Ana, Matos, Ilda, Freijo, Marta, Martins, Joao, Silveira, Fernando, Nadais, Goreti, Sousa, Filipa, Fraga, Carla, Santos Silva, Rosa, Lopes, Carlos, Gonçalves, Guilherme, Pinto, Clara, Sousa Braga, Jorge, and Leite, Maria Isabel

Published
2018
Full Text
View/download PDF

32. HLA and age of onset in myasthenia gravis

Author

Santos, Ernestina, Bettencourt, Andreia, da Silva, Ana Martins, Boleixa, Daniela, Lopes, Dina, Brás, Sandra, Costa, Paulo Pinho e, Lopes, Carlos, Gonçalves, Guilherme, Leite, Maria Isabel, and da Silva, Berta Martins

Published
2017
Full Text
View/download PDF

34. Treatment strategies and treatment-related adverse events in MG according to the age of onset.

Author

Moura, João, Fernandes, Joana, João Lima, Maria, Paula Sousa, Ana, Samões, Raquel, Martins Silva, Ana, and Santos, Ernestina

Subjects
ADVERSE health care events, AGE of onset, DISEASE duration, MEDICAL records, ELECTRONIC records, MYASTHENIA gravis
Abstract

Introduction: Early-onset (EOMG) and late-onset (LOMG) are distinct groups of MG patients. It is unclear if treatment strategies and treatment-related adverse events may differ according to the age of MG onset. Methods: This single-center retrospective study includes all MG patients followed at a tertiary center since 2007. We reviewed the electronic clinical records. Results: In total, 212 patients were identified, 142 (67.0%) females, with a median disease duration of 10years. The median age of symptom onset was 42.0 (26.0– 64.5) years, with 130 (61.3%) EOMG cases and 82 (38.7%) LOMG. EOMG were more frequently female, had longer disease duration and often more generalized MG (p < 0.001). Comorbidities were significantly more frequent in LOMG (67.1%) compared to EOMG (53.1%) (p = 0.002). Steroid-related adverse effects motivating the switch to steroid-sparing agents (82.0%) were different between groups, with hypertension, hypercholesterolemia, diabetes mellitus and malignancies being more common in LOMG. At the same time, osteoporosis and dyspepsia were more frequent in EOMG (p < 0.001). The most common first-line choice was azathioprine (45.8%), and rituximab was used in 4 patients (1.9%). Conclusion: Our study shows that treatment modalities are similar between EOMG and LOMG, while steroid-related adverse events appear to be distinct. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

40. Factors associated with the severity of COVID-19 outcomes in people with neuromuscular diseases: Data from the International Neuromuscular COVID-19 Registry

Author

Holt, James, Pritchard, Jane, Wall, Jasmine, Gamez, Josep, Oktay, YAVUZ, Macken, William L, Nesbitt, Victoria, Sansone, Valeria, Evangelista, Teresinha, Watson-Fargie, Taylor, Keddie, Stephen, Ramaratnam, Sridharan, Desai, Soaham, Yareeda, Sireesha, Rinaldi, Simon, Raga, Sharika, Menon R, Sarath, Sasidharan, Sandhya, Neshuku, Saara, Keh, Ryan, Geraldes, Ruth, Paterson, Ross W, Nortley, Ross, McFarland, Robert, Horvath, Rita, Thomas, Rhys H, Mehta, Puja R, Ambrose, Philip, Chinnery, Patrick F, Price, Olivia, Musumeci, Olimpia, Janssen, Mirian, Mancuso, Michelangelo, Dhamne, Megha, Zosmer, Maya, Ciocca, Matteo, Laura, Matilde, Skorupinska, Mariola, Househam, Liz, Clayton, Lisa, Saavedra, Lillian, Brennan, Kathryn, Wannop, Kate, Shakthi, K J S, Pizzamiglio, Chiara, Pitceathly, Robert D S, Lunn, Michael P, Brady, Stefen, De Marchi, Fabiola, Galan, Lucia, Heckmann, Jeannine M, Horga, Alejandro, Molnar, Maria J, Oliveira, Acary S B, Pinto, Wladimir B V R, Primiano, Guido, Santos, Ernestina, Schoser, Benedikt, Servidei, Serenella, Sgobbi Souza, Paulo V, Venugopalan, Vishnu, Hanna, Michael G, Dimachkie, Mazen M, Machado, Pedro M, Lim, Albert, Elsaddig, Amar, Juanatey, Ana, Romeiro, Ana, Themistocleous, Andreas, Kiss-Csenki, Annamaria, Guerrero Sola, Antonio, Patil, Anuja, Duggal, Ashish, Gabriel, Carolyn, Marshall, Charles, Record, Christopher, Allen, Claire, Bearden, David, Rathna Sabapathi, DeviPriya, R, Dileep, Vecchio, Domizia, Newman, Edward, Eshun, Edwin, Foo, Eng C, Bugiardini, Enrico, Burke, Georgina, Ramdharry, Gita, Gorman, Gràinne S, Kumar, Guru, Sivasathiaseelan, Harri, Braga Farias, Igor, Smuts, Izelle, and Groothuis, Jan T

Subjects
Male, Oxygen, Neurology, SARS-CoV-2, Humans, COVID-19, Metabolic Disorders Radboud Institute for Molecular Life Sciences [Radboudumc 6], Female, Neuromuscular Diseases, Registries, Neurology (clinical), Middle Aged, Disorders of movement Donders Center for Medical Neuroscience [Radboudumc 3]
Abstract

Contains fulltext : 291815.pdf (Publisher’s version ) (Open Access) BACKGROUND AND PURPOSE: Clinical outcome information on patients with neuromuscular diseases (NMDs) who have been infected with SARS-CoV-2 is limited. The aim of this study was to determine factors associated with the severity of COVID-19 outcomes in people with NMDs. METHODS: Cases of NMD, of any age, and confirmed/presumptive COVID-19, submitted to the International Neuromuscular COVID-19 Registry up to 31 December 2021, were included. A mutually exclusive ordinal COVID-19 severity scale was defined as follows: (1) no hospitalization; (2) hospitalization without oxygenation; (3) hospitalization with ventilation/oxygenation; and (4) death. Multivariable ordinal logistic regression analyses were used to estimate odds ratios (ORs) for severe outcome, adjusting for age, sex, race/ethnicity, NMD, comorbidities, baseline functional status (modified Rankin scale [mRS]), use of immunosuppressive/immunomodulatory medication, and pandemic calendar period. RESULTS: Of 315 patients from 13 countries (mean age 50.3 [±17.7] years, 154 [48.9%] female), 175 (55.5%) were not hospitalized, 27 (8.6%) were hospitalized without supplemental oxygen, 91 (28.9%) were hospitalized with ventilation/supplemental oxygen, and 22 (7%) died. Higher odds of severe COVID-19 outcomes were observed for: age ≥50 years (50-64 years: OR 2.4, 95% confidence interval [CI] 1.33-4.31; >64 years: OR 4.16, 95% CI 2.12-8.15; both vs.

Published
2023
Full Text
View/download PDF

48. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for eosinophilic granulomatosis with polyangiitis

Author

Grayson, Peter, Ponte, Cristina, Suppiah, Ravi, Robson, Joanna C., Craven, Anthea, Judge, Andrew, Khalid, Sara, Luqmani, Raashid, Watts, Richard, Merkel, Peter, Hutchings, Andrew, Grayson, Peter C., Luqmani, Raashid A., Merkel, Peter A., Gatenby, Paul, Watts, Richard A., Hill, Catherine, Ranganathan, Dwarakanathan, Kronbichler, Andreas, Blockmans, Daniel, Barra, Lillian, Carette, Simon, Pagnoux, Christian, Dhindsa, Navjot, Fifi-Mah, Aurore, Khalidi, Nader, Liang, Patrick, Milman, Nataliya, Pineau, Christian, Tian, Xinping, Wang, Guochun, Wang, Tian, Zhao, Ming hui, Tesar, Vladimir, Baslund, Bo, Hammam, Nevin, Shahin, Amira, Pirila, Laura, Putaala, Jukka, Hellmich, Bernhard, Henes, Jörg, Lamprecht, Peter, Neumann, Thomas, Schmidt, Wolfgang, Sunderkoetter, Cord, Szekanecz, Zoltan, Danda, Debashish, Das, Siddharth, Gupta, Rajiva, Rajasekhar, Liza, Dobashi, Hiroaki, Sharma, Aman, Wagh, Shrikant, Clarkson, Michael, Kawakami, Tamihiro, Kobayashi, Shigeto, Kono, Hajime, Makino, Hirofumi, Matsui, Kazuo, Muso, Eri, Suzuki, Kazuo, Ikeda, Kei, Takeuchi, Tsutomu, Tsukamoto, Tatsuo, Uchida, Shunya, Wada, Takashi, Yamada, Hidehiro, Yamagata, Kunihiro, Yumura, Wako, Lai, Kan Sow, Flores-Suarez, Luis Felipe, Hinojosa, Andrea, Rutgers, Bram, Tak, Paul Peter, Grainger, Rebecca, Quincey, Vicki, Stamp, Lisa, Besada, Emilio, Diamantopoulos, Andreas, Sznajd, Jan, Azevedo, Elsa, Geraldes, Ruth, Rodrigues, Miguel, Santos, Ernestina, Song, Yeong Wook, Moiseev, Sergey, Hocˇevar, Alojzija, Arimura, Yoshihiro, Cid, Maria Cinta, Moreno, Xavier Solanich, Atukorala, Inoshi, Berglin, Ewa, Molloy, Eamonn, Salvarani, Carlo, Schiavon, Franco, Tombetti, Enrico, Vaglio, Augusto, Amano, Koichi, Fujimoto, Shouichi, Harigai, Masayoshi, Hirano, Fumio, Hirahashi, Junichi, and Honma, Sakae

Abstract

Objective: To develop and validate revised classification criteria for eosinophilic granulomatosis with polyangiitis (EGPA). Methods: Patients with vasculitis or comparator diseases were recruited into an international cohort. The study proceeded in 5 phases: 1) identification of candidate criteria items using consensus methodology, 2) prospective collection of candidate items present at the time of diagnosis, 3) data-driven reduction of the number of candidate items, 4) expert panel review of cases to define the reference diagnosis, and 5) derivation of a points-based risk score for disease classification in a development set using least absolute shrinkage and selection operator logistic regression, with subsequent validation of performance characteristics in an independent set of cases and comparators. Results: The development set for EGPA consisted of 107 cases of EGPA and 450 comparators. The validation set consisted of an additional 119 cases of EGPA and 437 comparators. From 91 candidate items, regression analysis identified 11 items for EPGA, 7 of which were retained. The final criteria and their weights were as follows: maximum eosinophil count ≥1 × 109/liter (+5), obstructive airway disease (+3), nasal polyps (+3), cytoplasmic antineutrophil cytoplasmic antibody (ANCA) or anti–proteinase 3 ANCA positivity (−3), extravascular eosinophilic predominant inflammation (+2), mononeuritis multiplex/motor neuropathy not due to radiculopathy (+1), and hematuria (−1). After excluding mimics of vasculitis, a patient with a diagnosis of small- or medium-vessel vasculitis could be classified as having EGPA if the cumulative score was ≥6 points. When these criteria were tested in the validation data set, the sensitivity was 85% (95% confidence interval [95% CI] 77–91%) and the specificity was 99% (95% CI 98–100%). Conclusion: The 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for EGPA demonstrate strong performance characteristics and are validated for use in research.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results